Prescriptions of GLP-1 weight loss drugs to American children aged 8 to 11 were 310 times more common by June 2026 than in 2019, according to a study published in the journal Pediatrics. Across the full study period, 20,282 children in that age group received one.
Both halves of that finding matter, and the second half is getting lost. A 310-fold increase sounds enormous. It is calculated from a 2019 baseline of 0.03 percent, close to zero. Across the whole period, 0.6 percent of children aged 8 to 11 with obesity and without diabetes ever received a prescription, versus 0.9 percent of adolescents aged 12 to 17, according to the NYU Langone Health study announcement.
For a parent wondering whether this is reshaping their child's classroom, the answer is not yet. Roughly one in five American children has obesity, and the overwhelming majority are not being prescribed these medications.
The Numbers Behind the Headline Multiplier
Researchers led by NYU Langone Health analyzed electronic health records for 3,520,531 children who had obesity and did not have diabetes, drawn from Epic Cosmos, a national dataset covering more than 300 million patients across 2,067 hospitals and 47,100 clinics. The study period ran from January 2019 through mid-June 2026.
Prescribing skewed toward the sickest children. About 93.7 percent of those who received a prescription had severe obesity, compared with children not prescribed the drugs, among whom 51.5 percent did. About 65.2 percent of recipients had at least one obesity-related condition such as high cholesterol, high blood pressure, or sleep apnea, compared with 19.6 percent of the rest. Older children were more likely to receive a prescription than younger ones, and girls more often than boys. Wegovy was the drug most often prescribed.
This is a retrospective cross-sectional analysis of prescribing patterns, not a clinical trial. It measures who was prescribed what and when. It does not measure whether children lost weight, benefited, or had side effects, and it cannot tell whether prescriptions were filled or continued. According to researcher disclosure statements accompanying the release, the lead investigator has served on an advisory board for Boehringer Ingelheim and a senior co-author discloses consulting and speaking honoraria from several drug companies, none of which the institution says relate to this work.
Off Label by Definition, Because Approvals Begin at Twelve
None of the three drugs studied is approved by the FDA for children under 12. Wegovy and Saxenda carry pediatric indications that begin at age 12, and Zepbound is approved for adults only. Every prescription in the 8 to 11 age group is therefore off-label, although pediatric obesity guidelines do allow clinicians to consider these medications in children as young as 8.
Off-label is not the same as improper. Physicians prescribe outside approved age ranges routinely, particularly in pediatrics, where trials lag clinical need. But it changes what parents are entitled to ask. There is no FDA-reviewed dosing guidance for this age group, no approved safety labeling, and no long-term outcome data in children this young.
Trials in children as young as 6 are underway, which is precisely why the researchers argue for monitoring now rather than after the fact. Dr. Babak J. Orandi, the study's lead investigator and an associate professor at NYU Grossman School of Medicine, said in coverage of the prescribing analysis that absolute numbers remain low but that "GLP-1 use is accelerating rapidly."
Income Gaps Are Already Visible in Who Receives Them
One finding deserves more attention than the multiplier. Children in communities with less social vulnerability, a measure closely tied to neighborhood income, received prescriptions at a rate of 76.1 per 10,000 compared with 49.2 per 10,000 in the most vulnerable communities. That is roughly 55 percent more likely.
That is an early signal of a familiar pattern. These are expensive medications, frequently excluded from coverage or subject to prior authorization, and reaching them requires access to a pediatric clinic willing to prescribe. Study co-senior author Allan B. Massie, an associate professor in the departments of surgery and population health at NYU Grossman School of Medicine, argued that physicians and policymakers share responsibility for making sure the drugs reach beyond families with insurance and clinic access.
For households, that is a cost question worth raising early. Many commercial plans require documented participation in a supervised weight management program before approving coverage. State Medicaid coverage for anti-obesity medications varies considerably. Parents facing a denial can ask the prescriber about prior authorization, the appeals process, and whether a covered alternative exists.
Families should also be wary of the online market for these drugs. Compounded and unverified semaglutide sold through websites and social media sellers has drawn repeated federal warnings, and a dosing error carries more consequences in a smaller body.
Questions Worth Bringing to a Pediatrician
Nothing in this study is a reason to start or stop a medication, and it is not a recommendation for any individual child. It is a description of what is already happening in American clinics.
Parents who are weighing the topic can ask a pediatrician a few concrete things. What is my child's BMI percentile, and has it been tracked over time? Are there obesity-related conditions already present, such as elevated blood pressure, abnormal lipids, fatty liver, or sleep apnea? What behavioral and family-based treatment has been tried, and for how long? If medication is increased, what is the monitoring plan, what side effects should we watch for, and what is the plan if we stop?
Common GLP-1 side effects include nausea, vomiting, diarrhea, and constipation, and they are frequently why people discontinue. Parents should seek prompt medical guidance for persistent vomiting, severe abdominal pain, signs of dehydration, or any rapid unexplained change in a child's eating behavior. No child should be started on, or taken off, a prescription without a clinician's involvement.
The meaningful question is not whether the multiplier is large but whether prescribing is concentrated among children with genuine cardiometabolic risk. On that point, the study is reassuring, since nearly all recipients had severe obesity and most had a related condition.
What comes next is more data. The pediatric trials underway in younger children will report over the coming years, and their results will shape whether FDA approvals extend below age 12. Until then, prescribing in this age group remains a clinical judgment made case by case, and the researchers say long-term monitoring of children already receiving these drugs is the gap most in need of closing.
Key Questions Answered
What did the study actually measure? It measured how often GLP-1 medications were prescribed to children with obesity and without diabetes, using electronic health records for 3,520,531 children. It did not measure weight loss, side effects, or long-term outcomes.
Is a 310-fold increase as alarming as it sounds? It reflects growth from a near-zero baseline of 0.03 percent. Over the full study period, 0.6 percent of children aged 8 to 11 with obesity received a prescription, a smaller share than among adolescents aged 12 to 17.
Are these drugs approved for children under 12? No. Wegovy and Saxenda are approved starting at age 12, and Zepbound is approved for adults only. Prescribing to children aged 8 to 11 is off-label.
Which children were most likely to receive a prescription? Those with severe obesity, which described 93.7 percent of recipients, and those with an obesity-related condition, which described 65.2 percent. Children in less socially vulnerable communities were about 55 percent more likely to receive one.
What side effects should parents watch for? Nausea, vomiting, diarrhea, and constipation are the most common. Persistent vomiting, severe abdominal pain, signs of dehydration, or rapid changes in eating behavior warrant prompt medical attention.
Does this change what doctors are advised to do? No. The study describes prescribing patterns. It does not alter clinical guidelines, and treatment decisions for any individual child remain a matter for that child's clinician.
What if insurance will not cover the medication? Ask the prescriber about prior authorization requirements, the appeals process, whether a covered alternative exists, and whether the manufacturer offers a patient assistance program. Medicaid coverage for anti-obesity medications differs by state.
